RDHL
RedHill Biopharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.72
+1.63%Year over year
Reported trailing growth
- Revenue
- +157.6%
- EBITDA
- +59.5%
- EBIT
- +48.5%
- EPS
- +90.7%
- Free cash flow
- +66.1%
- Operating cash flow
- +66.2%
Forward estimates
Based on analyst estimates
- Revenue
- +910.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -83.3%
- EBITDA
- -0.8%
- EBIT
- +45.9%
- Net income
- +94.8%
- EPS
- +100.0%
- Free cash flow
- -3.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025